Syndax Pharmaceuticals, Inc.
SNDXDrugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 2 past
No catalysts found.
How SNDX's past catalysts played out
Revumenib
Colorectal Cancer
Intensive Chemotherapy Regimen
Acute Myeloid Leukemias
Aromatase Inhibitor (AI) Therapy
ER+ Breast Cancer
cobicistat
Acute Myeloid Leukemia
Axatilimab
Chronic Graft-versus-host-disease
avelumab
Epithelial Ovarian Cancer
entinostat
Non-Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Revumenib | Phase 3 | Colorectal Cancer | - | - |
Intensive Chemotherapy Regimen | Phase 3 | Acute Myeloid Leukemias | - | - |
Aromatase Inhibitor (AI) Therapy | Phase 2 | ER+ Breast Cancer | - | - |
cobicistat | Phase 2 | Acute Myeloid Leukemia | - | - |
Axatilimab | Phase 2 | Chronic Graft-versus-host-disease | - | - |
avelumab | Phase 2 | Epithelial Ovarian Cancer | - | - |
entinostat | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Frequently asked questions
What is in Syndax Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Syndax Pharmaceuticals, Inc.'s (SNDX) pipeline across Phase 3, Phase 2. Its lead program is Revumenib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Syndax Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Syndax Pharmaceuticals, Inc. (SNDX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SNDX biotech catalysts?→
Add SNDX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Syndax Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.